<\/p>\n
Solu-Medrol<\/strong> is a sterile powder for reconstitution from Pfizer containing methylprednisolone sodium succinate 125 mg \/ 2 mL Act-O-Vial<\/strong> \u2014 highly water-soluble pro-drug ester<\/strong> of methylprednisolone designed for rapid intravenous (IV) bolus or infusion<\/strong> when an immediate, large dose of glucocorticoid is needed. Onset of action is within minutes to 1 hour<\/strong>. Pou\u017e\u00edv\u00e1 se na high-dose pulse therapy<\/strong> in MS relapse (1 g IV daily for 3–5 days), severe acute asthma, anaphylaxis after epinephrine, severe lupus or vasculitis flare, transplant rejection (induction and rescue), sight-threatening optic neuritis, and severe inflammatory ophthalmic disease. Lower doses (40–125 mg IV) are used as second-line in anaphylaxis, severe allergic reactions, and acute spinal cord injury (controversial). Pulse therapy carries a real risk of severe arrhythmia and sudden cardiac death<\/strong> — cardiac monitoring is standard during gram-doses. Other acute risks include severe psychiatric reaction, hyperglycaemia (especially in diabetes), and anaphylaxis to the drug itself. This is a hospital and supervised-clinic medication, not for patient self-administration.<\/strong><\/p>\n<\/div>\n <\/p>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Solu-Medrol is a sterile powder for reconstitution and intravenous bolus or infusion manufactured by Pfizer containing methylprednisolone sodium succinate<\/strong> — a synthetic corticosteroid in the glucocorticoid class. Glucocorticoids are the most powerful broad-spectrum anti-inflammatory and immunosuppressive drugs available, with effects across almost every tissue and organ system.<\/p>\n Solu-Medrol is Pfizer's original methylprednisolone sodium succinate — the standard hospital\/emergency-room IV steroid. The 125 mg \/ 2 mL Act-O-Vial is the most-stocked strength worldwide and is used for severe acute asthma, anaphylaxis (after epinephrine), severe COPD exacerbation, MS relapse (in combination with additional vials for gram-doses), transplant rejection and severe autoimmune flares. Designed for in-hospital or supervised-clinic use, not patient self-administration.<\/p>\n Methylprednisolone 4 mg is approximately equivalent to prednisolone 5 mg (potency ratio ~5). The physiological daily cortisol output of a healthy adult is approximately 5–7.5 mg of prednisolone-equivalent — any dose above that is “supraphysiological” and begins to suppress the hypothalamic-pituitary-adrenal (HPA) axis.<\/p>\n Why methylprednisolone sodium succinate IV?<\/strong> Methylprednisolone itself is poorly water-soluble — impossible to inject IV at the gram-doses needed for pulse therapy. The sodium succinate ester is highly water-soluble, dissolves rapidly in the supplied diluent, and is hydrolysed in the blood to active methylprednisolone within minutes. The Act-O-Vial dual-chamber design keeps powder and diluent separate until reconstitution, extending shelf life and reducing pharmacist preparation time in the emergency setting where every minute counts.<\/p>\n Methylprednisolone enters cells, binds the intracellular glucocorticoid receptor<\/strong>, and the receptor-drug complex translocates to the nucleus where it alters transcription of hundreds of genes. The end result is a broad dampening of the inflammatory cascade:<\/p>\n Clinical onset (IV): genomic anti-inflammatory effects within 1–4 hours<\/strong>. At gram-doses, additional rapid non-genomic membrane-stabilising effects<\/strong> appear within minutes, contributing to the immediate symptomatic benefit seen in MS relapse, severe asthma and acute spinal cord injury.<\/p>\n Solu-Medrol is used wherever an immediate, very large dose of glucocorticoid is needed and the patient cannot wait for oral absorption.<\/p>\n Solu-Medrol is ne<\/strong> appropriate for: maintenance therapy (switch to oral as soon as the patient can swallow), undiagnosed shock or sepsis without specialist review, or routine outpatient use.<\/p>\n Solu-Medrol is supplied as 125 mg \/ 2 mL Act-O-Vial<\/strong>. The Act-O-Vial dual-chamber system contains the lyophilised methylprednisolone sodium succinate powder in the upper chamber and the bacteriostatic water diluent in the lower chamber, separated by a stopper. Activate by pressing down on the plastic plunger to depress the stopper and release the diluent into the powder.<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Solu-Medrol?<\/h2>\n
How Does Solu-Medrol Work?<\/h2>\n
\n
Pou\u017eit\u00ed a indikace<\/h2>\n
High-dose pulse therapy (gram-doses)<\/h3>\n
\n
Lower-dose IV (40–500 mg)<\/h3>\n
\n
Solu-Medrol Dosage and How to Use<\/h2>\n
Typical adult IV doses<\/h3>\n